Our goal is to enable our partners to precisely target drugs and biologics to the colon, or to both the small intestine and colon, for local or systemic delivery based on the GEMICEL® oral delivery platform

Partnering history and goals
TheraBiome partnered with Assembly Bio (NASDAQ: ASMB) and later Assembly/ Allergan for 7+ years to advance GEMICEL technology to the clinic. TheraBiome regained full patent and trademark rights to GEMICEL® technology in 2021, following acquisition of Allergan by Abbvie, and resulting change in corporate strategy. 
TheraBiome is keenly interested in exploring partnering opportunities. This technology holds promise in Inflammatory Bowel Disease (IBD), e.g., Crohn’s and ulcerative colitis and other GI-related diseases as well as enables enteral administration for local and systemic applications. GEMICEL is differentiated and provides access to renewed product vigor with extended life cycle management.

Team with controlled drug delivery experience
Founder Mohan Kabadi, PhD is ex-Novartis, Roche and BMS; he has deep pharmaceutical development, formulation and manufacturing expertise. Co-founder, Jerome Schentag, PharmD is a PK/PD expert and licensed the SmartPill to Medtronic. Partnership advisor Michael Atkin is a biotech leader, ex-BMS; He closed over a dozen life sciences partnerships excluding university licenses. Amit Jolly has investment and business development experience. 
• Mohan Kabadi, PhD, Inventor & founder
• Jerome J. Schentag PharmD, Co-founder
• Michael Atkin, Partnership advisor
• Amit Jolly, BD Advisor

Intellectual Property
TheraBiome holds 5 issued US patents for targeted GI tract drug (9,907,755, 10,369,111 & 11,590,083) and vaccine delivery (10,588,857 & 11,622,936). 19 issued patents in other countries
Patent Counsel: Gearhart Law LLC